Compounded GLP-1 ban: what the FDA proposal means for patients

TL;DR

The FDA announced on April 30, 2026 that it intends to permanently exclude semaglutide, tirzepatide, and liraglutide from the list of bulk substances that 503B outsourcing facilities can use to make compounded medications. If finalised, this closes the door on compounded GLP-1 drugs permanently - even if branded versions go into shortage again. The public comment window closes June 29, 2026.

Hundreds of thousands of patients have been using compounded GLP-1 medications at $150 to $300 per month - a fraction of the $1,000-plus monthly cost of branded Ozempic or Wegovy. For many of them, the compounded version was the only financially viable path. That path is now being shut.

What the FDA is actually proposing

Under Section 503B of the Federal Food, Drug, and Cosmetic Act, large-scale compounding facilities (called outsourcing facilities) can prepare medications from bulk drug substances only under specific conditions - primarily when the branded version is on the FDA's drug shortage list. Semaglutide and tirzepatide were added to that shortage list in 2022 as demand exploded and Novo Nordisk and Eli Lilly couldn't keep up with supply.

The shortage has since been resolved. The FDA declared the semaglutide shortage over in early 2025, which triggered enforcement actions against compounders that began in late 2024. Now the agency is going further: it wants to formally and permanently remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list entirely. The practical effect is that even if a shortage returns in future, compounding of these specific drugs would remain prohibited.

FDA Commissioner Marty Makary stated the reasoning plainly: "When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need."

Why the FDA is moving now

The agency cited 455 or more adverse event reports linked to compounded semaglutide, and over 320 for compounded tirzepatide. The reported problems included dosing errors from multi-dose vials - compounded versions are often supplied in vials requiring patients to draw and measure their own doses, unlike the pre-filled pens used for branded products. Some reports involved counterfeit products circulating through online channels that patients believed were compounded GLP-1 medications.

The FDA's position is that this safety risk is no longer justified by a shortage-based public health need. Branded products are available - if not affordable for everyone.

Which drugs are affected

• Semaglutide: Ozempic (diabetes), Wegovy (weight loss), Rybelsus (oral diabetes)
• Tirzepatide: Mounjaro (diabetes), Zepbound (weight loss)
• Liraglutide: Victoza (diabetes), Saxenda (weight loss) - already declining in prescriptions as semaglutide and tirzepatide dominate

Notably, orforglipron (Foundayo) is not on this list - it's a small-molecule oral drug rather than a peptide, and its chemistry makes bulk compounding essentially impossible anyway. So the emerging oral GLP-1 category isn't directly affected by this proposal.

What happens to patients who relied on compounded versions

This is where the proposal gets difficult. A significant number of patients - particularly those without insurance coverage, those who've exhausted manufacturer savings programs, and those with incomes too high for assistance programs but too low to pay cash prices - were accessing GLP-1 medications through compounding pharmacies specifically because the price was manageable.

The FDA's guidance to pharmacists is to counsel patients toward manufacturer savings programs and legitimate cost-assistance initiatives. In practice, those programs have income caps and coverage limits that exclude many people. The Novo Nordisk savings program caps eligibility. The Eli Lilly savings card has similar restrictions.

Real options remaining for patients affected include:

• Manufacturer patient assistance programs - check eligibility carefully, as limits have tightened
• The Medicare GLP-1 Bridge program launching July 1, 2026, which caps copays at $50 per month for qualifying Medicare Part D enrollees
• Employer-sponsored health plans that now cover GLP-1 medications - coverage has expanded significantly in 2025-2026
• GoodRx and similar discount programs, which can reduce cash prices at certain pharmacy chains
• Switching to Foundayo (orforglipron) if oral GLP-1 suits your situation - it may carry different pricing dynamics as a new entrant

How to submit a public comment before June 29

The FDA's proposed rule is open for public comment until June 29, 2026. Patient experiences - particularly those describing the financial hardship of losing access to compounded versions - are directly relevant and legally considered in the rulemaking process. Comments can be submitted at regulations.gov by searching for the relevant docket number. Patient advocacy groups including the Obesity Medicine Association have been coordinating comment submissions.

This is not a performative comment period. The FDA is legally required to respond to substantive comments before finalising a rule, and in prior compounding disputes, significant patient comment volume has influenced final regulatory language - even if the core outcome didn't change.

The bigger access picture

The compounding ban lands at the same moment the Medicare Bridge program launches - a coincidence of timing that reflects the messy, overlapping nature of US drug access policy. For patients under 65 without adequate insurance, the options are genuinely narrowing. For patients on Medicare, July 1 brings a meaningful improvement.

The longer-term trajectory depends on whether Novo Nordisk and Eli Lilly lower list prices for Wegovy and Zepbound once compounding competition disappears - something both companies have resisted doing while compounding alternatives existed. Several analysts are watching this closely. The FDA's proposal may ironically accelerate pricing negotiations if patient access organisations push hard enough.

At GLP-1 Shield, we track access developments like this because they directly affect who can stay on GLP-1 therapy and for how long. The nutritional support strategy you build while on these medications becomes even more relevant if continuity of treatment is uncertain.

Frequently asked questions

Is compounded semaglutide already banned?

Enforcement actions against compounders began in late 2024 after the FDA declared the semaglutide shortage resolved. The April 2026 proposal would formalise a permanent ban under the 503B bulks list rules. Until the rule is finalised - which requires a public comment period closing June 29, 2026 - the legal landscape for individual compounders may still vary.

Can I still get compounded tirzepatide?

The FDA's enforcement against compounded tirzepatide also began with the shortage resolution. The new proposal adds tirzepatide to the same permanent exclusion list as semaglutide. If you're currently obtaining compounded tirzepatide, discuss your options with your prescribing physician now rather than waiting for the rule to be finalised.

What are the cheapest alternatives if compounded GLP-1 drugs disappear?

The main options are manufacturer savings programs (income-limited), the Medicare Bridge at $50/month starting July 1, 2026 (Medicare Part D enrollees), employer health plan coverage (expanding in 2025-2026), and GoodRx discount pricing at certain pharmacies. Foundayo (orforglipron), the new oral GLP-1, may carry different pricing dynamics as it enters the market.

Why did the FDA allow compounded GLP-1 drugs in the first place?

Compounding is permitted when an FDA-approved drug is on the official drug shortage list - a status assigned when branded supply cannot meet demand. Semaglutide and tirzepatide were added to the shortage list in 2022 as prescriptions grew exponentially and manufacturers couldn't scale fast enough. Once the shortage was resolved, the legal basis for large-scale compounding under 503B rules ended.